265 related articles for article (PubMed ID: 22200690)
21. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis.
Rajendran R; Rajeesh MP; Shaikh S; Shanthi ; Pillai MR
Indian J Dent Res; 2006; 17(4):161-6. PubMed ID: 17217211
[TBL] [Abstract][Full Text] [Related]
23. Comparative expression of matrix metalloproteinases in internal malignancies and paired cutaneous metastatic lesions.
Kim TH; Jung JY; Roh HJ; Chung KY; Roh MR
Am J Dermatopathol; 2015 May; 37(5):381-8. PubMed ID: 25062266
[TBL] [Abstract][Full Text] [Related]
24. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
[TBL] [Abstract][Full Text] [Related]
25. Correlation of survivin and MMP9 expressions with prognosis and clinicopathological parameters in surface epithelial ovarian carcinomas.
Kuşku Cabuk F; Yığıt S; Demır L; Cakalağaoğlu F; Tarhan O
Turk Patoloji Derg; 2014; 30(1):30-7. PubMed ID: 24448704
[TBL] [Abstract][Full Text] [Related]
26. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.
Ekekezie II; Thibeault DW; Simon SD; Norberg M; Merrill JD; Ballard RA; Ballard PL; Truog WE
Pediatrics; 2004 Jun; 113(6):1709-14. PubMed ID: 15173495
[TBL] [Abstract][Full Text] [Related]
27. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Kamat AA; Fletcher M; Gruman LM; Mueller P; Lopez A; Landen CN; Han L; Gershenson DM; Sood AK
Clin Cancer Res; 2006 Mar; 12(6):1707-14. PubMed ID: 16551853
[TBL] [Abstract][Full Text] [Related]
28. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.
Knittel T; Mehde M; Grundmann A; Saile B; Scharf JG; Ramadori G
Histochem Cell Biol; 2000 Jun; 113(6):443-53. PubMed ID: 10933221
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
31. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
[TBL] [Abstract][Full Text] [Related]
32. Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients.
Baumgart E; Lenk SV; Loening SA; Jung K
Hum Reprod; 2002 Nov; 17(11):2919-23. PubMed ID: 12407049
[TBL] [Abstract][Full Text] [Related]
33. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
34. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
35. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
37. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms.
Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H
Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
[TBL] [Abstract][Full Text] [Related]
39. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
40. Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis.
Trudel D; Desmeules P; Turcotte S; Plante M; Grégoire J; Renaud MC; Orain M; Bairati I; Têtu B
Mod Pathol; 2014 Oct; 27(10):1394-404. PubMed ID: 24603589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
